Inmolecule Nanotech (XPAR:MLINA) Scaled Net Operating Assets: 0.65 (As of Dec. 2024)


XPAR:MLINA Inmolecule Nanotech SA XPAR:MLINA
6 GF Score
Price €4.08
! 2 Warning Signs
View Full Analysis

What is Inmolecule Nanotech Scaled Net Operating Assets?

Inmolecule Nanotech XPAR:MLINA 6 Scaled Net Operating Assets is 0.65 as of Dec. 2024. GuruFocus rates XPAR:MLINA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Inmolecule Nanotech's operating assets for the quarter that ended in Dec. 2024 was €12.22 Mil. Inmolecule Nanotech's operating liabilities for the quarter that ended in Dec. 2024 was €2.90 Mil. Inmolecule Nanotech's Total Assets for the quarter that ended in Dec. 2023 was €14.42 Mil. Therefore, Inmolecule Nanotech's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was 0.65.

Inmolecule Nanotech Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Inmolecule Nanotech's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech Scaled Net Operating Assets Chart

Inmolecule Nanotech Annual Data
Trend Dec23 Dec24
Scaled Net Operating Assets
0.78 0.65

Inmolecule Nanotech Semi-Annual Data
Dec23 Dec24
Scaled Net Operating Assets 0.78 0.65

XPAR:MLINA vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Inmolecule Nanotech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inmolecule Nanotech Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Inmolecule Nanotech's Scaled Net Operating Assets falls into.


XPAR:MLINA
6GF Score
Inmolecule Nanotech SA XPAR:MLINA
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inmolecule Nanotech Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Inmolecule Nanotech's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(12.216-2.902)/14.42
=0.65

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=12.303 - 0.087
=12.216

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4.845 - 1.938 - 0.005
=2.902

Inmolecule Nanotech's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2024 )
=(Operating Assets (Q: Dec. 2024 )-Operating Liabilities (Q: Dec. 2024 ))/Total Assets (Q: Dec. 2023 )
=(12.216-2.902)/14.42
=0.65

where

Operating Assets(Q: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=12.303 - 0.087
=12.216

Operating Liabilities(Q: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4.845 - 1.938 - 0.005
=2.902

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.65 mean?
Inmolecule Nanotech (XPAR:MLINA) has a Scaled Net Operating Assets of 0.65 as of Dec. 2024. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Inmolecule Nanotech and its competitors.
Is Inmolecule Nanotech's Scaled Net Operating Assets too high?
Inmolecule Nanotech's current Scaled Net Operating Assets is 0.65. Overall, Inmolecule Nanotech has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's Scaled Net Operating Assets compare to VRTX and REGN?
Inmolecule Nanotech's Scaled Net Operating Assets of 0.65 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Inmolecule Nanotech and its competitors. Inmolecule Nanotech's current Scaled Net Operating Assets is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current Scaled Net Operating Assets of 0.65. The current Scaled Net Operating Assets is 0.65. Inmolecule Nanotech's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current Scaled Net Operating Assets is 0.65 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inmolecule Nanotech Business Description

Address Paseo de la Castellana 91, 4th Floor, Madrid, ESP, 28046
Inmolecule Nanotech SA is a research and development company. The company provides health care, home care and personal care products.
6GF Score

Get the complete analysis for XPAR:MLINA

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price